RELATED PARTY TRANSACTIONS

12 Months Ended

Dec. 31, 2019

NOTE 17: RELATED PARTY TRANSACTIONS

The following table sets forth related party transaction expenses recorded during the respective periods:


	For the Years Ended
	December 31,
	2019		2018

Research and development	$	302,000	$	138,000
General and administrative		—		—
Total	$	302,000	$	138,000

Sponsored Research Agreement with The Baylor College of Medicine (“BCM”). On November 16, 2018, in furtherance of the BCM License Agreement and as contemplated by the terms thereof, the Company entered in a Sponsored Research Agreement (“SRA”) with BCM, which provided for the conduct of research for the Company by credentialed personnel at BCM’s Center for Cell and Gene Therapy.

During the years ended December 31, 2019 and 2018, the Company incurred approximately $69,000 and $77,000, respectively, to BCM under the SRA.

Clinical Supply Agreement with BCM. On September 9, 2019, in furtherance of the BCM License Agreement and as contemplated by the terms thereof, the Company entered in a Clinical Supply Agreement (“CSA”) with BCM, which provided for BCM to provide to the Company multi tumor antigen specific products.

During the year ended December 31, 2019, the Company did not incur any expenses under the CSA.

Consulting Agreement with Dr. Juan Vera. On October 19, 2018, after the closing of the Company’s merger, the Company entered into a consulting agreement with Dr. Juan Vera, a member of the Company’s board of directors, to serve as the Company’s Chief Development Officer. On September 1, 2019, Dr. Vera became an employee of the Company and his consulting agreement was terminated.

During the years ended December 31, 2019 and 2018, the Company incurred approximately $233,000 and $61,000, respectively, of expenses under Dr. Vera’s consulting agreement.